留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

林莉莉 姚囡囡 吴珏 刘志宏 宋洪涛

林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
引用本文: 林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
Citation: LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018

糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

doi: 10.3969/j.issn.1006-0111.2019.05.018

Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis

  • 摘要: 目的 比较糠酸氟替卡松/维兰特罗复方剂(FF/VI)与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异。 方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库,纳入随机对照试验,采用Cochrane系统评价方法进行评价。 结果 共纳入10个研究,共9 811例患者。在疗效上,FF/VI组与对照组相比,提高患者的1秒用力呼气量谷值[WMD=0.09,95% CI(0.05,0.13),P=0.000]和哮喘控制测试评分[WMD=0.63,95% CI(0.24,1.03),P=0.002]。在耐受性方面,FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15,95% CI(0.98,1.36),P=0.000]。 结论 用FF/VI治疗哮喘在疗效方面具有优势,且具有良好的耐受性。其每日1次的用药频次可提高患者依从性,值得推荐使用。
  • [1] 林燕萍.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[C].中国中西医结合变态反应学术会议.2009.
    [2] BATEMAN E D,HURD S S,BARNES P J,et al. Global strategy for asthma management and prevention:GINA executive summary[J].Eur Respir J,2008,31(1):143-178.
    [3] BLAIS L,SUISSA S,BOIVIN J F,et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma[J].Thorax,1998,53(12):1025-1029.
    [4] SHIMODA T,OBASE Y,KISHIKAWA R,et al. Impact of inhaled corticosteroid treatment on 15-year longitudinal respiratory function changes in adult patients with bronchial asthma[J].Int Arch Allergy Immunol,2013,162(4):323-329.
    [5] SUISSA S,ERNST P,BENAYOUN S,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma[J].N Engl J Med,2000,343(5):332-336.
    [6] TOY E L,BEAULIEU N U,MCHALE J M,et al. Treatment of COPD:Relationships between daily dosing frequency,adherence,resource use,and costs[J].Respir Med,2011,105(3):435-441.
    [7] GAMBLE J,STEVENSON M,MCCLEAN E,et al. The prevalence of nonadherence in difficult asthma[J]. Am J Respir Crit Care Med,2009,180(9):817-822.
    [8] BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
    [9] DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
    [10] JACQUES L,BAKERLY N D,NEW J P,et al. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study[J].J Asthma,2018:1-10.
    [11] 张菲,江兵,缪李丽.糠酸氟替卡松治疗支气管哮喘疗效及安全性的系统评价[J].中国循证医学杂志,2017,17(1):33-39.
    [12] MOHER D,LIBERATI A,TETZLAFF J,et al. Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement[J].Int J Surg,2010,8(5):336-341.
    [13] BUSSE W W,O'BYRNE P M,BLEECKER E R,et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2-agonist vilanterol administered once daily for 52 weeks in patients ≥ 12 years old with asthma:a randomised trial[J].Thorax,2013,68(6):513-520.
    [14] WOODCOCK A,BLEECKER E R,LOTVALL J,et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma:a randomized trial[J].Chest,2013,144(4):1222-1229.
    [15] O'BYRNE P M,BLEECKER E R,BATEMAN E D,et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma[J].Eur Respir J,2014,43(3):773-782.
    [16] BATEMAN E D,O'BYRNE P M,BUSSE W W,et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone[J].Thorax,2014,69(4):312-319.
    [17] BLEECKER E R,LOTVALL J,O'BYRNE P M,et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma:a randomized trial[J].J Allergy Clin Immunol Pract,2014,2(5):553-561.
    [18] LIN J,KANG J,LEE S H,et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients:A randomized trial[J].Respir Med,2015,109(1):44-53.
    [19] BERNSTEIN D I,BATEMAN E D,WOODCOCK A,et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma[J]. J Asthma,2015,52(10):1073-1083.
    [20] GROSS A S,GOLDFRAD C,HOZAWA S,et al. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase Ⅱb/Ⅲ trials[J]. Bmc Pulm Med,2015,15(1).
    [21] DEVILLIER P,HUMBERT M,BOYE A,et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma:An open-label,randomized,controlled trial[J].Respir Med,2018,141:111-120.
    [22] BIGGADIKE K. Fluticasone furoate/fluticasone propionate-different drugs with different properties[J].Clin Respir J,2011,5(3):183-184.
    [23] BIGGADIKE K,BLEDSOE R K,HASSELL A M,et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocoricoid receptor ligand binding domain[J].J Med Chem,2008,51(12):3349-3352.
    [24] SALTER M,BIGGADIKE K,MATTHEWS J L,et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease[J].Am J Physiol-Lung C,2007,293(3):L660-L667.
    [25] VALOTIS A,HOGGER P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate[J].Respir Res,2007,8:54.
    [26] ALLEN A,BAREILLE P J,ROUSELL V M. Fluticasone furoate,a novel inhaled corticosteroid,demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate[J].Clin Pharmacokinet,2013,52(1):37-42.
    [27] ROSSIOS C,TO Y,TO M,et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells[J].Eur J Pharmacol,2011,670(1):244-251.
    [28] PROCOPIOU P A,BARRETT V J,BEVAN N J,et al. Synthesis and structure activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation:an antedrug approach[J].J Med Chem,2010,53(11):4522-4530.
  • [1] 葛佳佳, 张莹莹.  β-内酰胺类联合大环内酯类药物治疗儿童社区获得性肺炎的有效性与安全性的Meta分析 . 药学实践与服务, 2021, 39(3): 274-279. doi: 10.12206/j.issn.1006-0111.202007077
    [2] 岑菁, 吕珊, 唐敏.  头孢他啶/阿维巴坦治疗碳青霉烯类耐药肠杆菌感染疗效和安全性的Meta分析 . 药学实践与服务, 2021, 39(4): 373-378. doi: 10.12206/j.issn.1006-0111.202007011
    [3] 廖小兰, 汪滢, 黄爱文, 郭秀强, 赖彦岚, 宋洪涛.  安罗替尼在治疗癌症患者中高血压的发生率和发生风险:一项系统评价和Meta分析 . 药学实践与服务, 2020, 38(6): 552-557. doi: 10.12206/j.issn.1006-0111.202008069
    [4] 金飞虹, 陈婕, 杨文超.  银杏二萜内酯葡胺注射液治疗脑梗死的疗效及安全性的Meta分析 . 药学实践与服务, 2019, 37(1): 80-85. doi: 10.3969/j.issn.1006-0111.2019.01.019
    [5] 熊娟, 鹿辉, 王荣, 贾正平.  超重可能是急性高山病的危险因素:一项Meta分析 . 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
    [6] 郑丽丽, 轩辕欢, 姜倩, 范芳芳, 姚莉, 赵生俊.  比较万古霉素持续输注与间断输注引起肾毒性的荟萃分析 . 药学实践与服务, 2018, 36(2): 136-139,146. doi: 10.3969/j.issn.1006-0111.2018.02.009
    [7] 白向荣, 程红勤, 张雁, 金颖.  两性霉素B膀胱冲洗治疗真菌尿的荟萃分析 . 药学实践与服务, 2018, 36(4): 379-384. doi: 10.3969/j.issn.1006-0111.2018.04.021
    [8] 应茵, 陆绪亮, 董威夷, 宋洪涛.  10 mg多廿烷醇与等剂量阿托伐他汀在血脂异常患者中调脂疗效比较的荟萃分析 . 药学实践与服务, 2017, 35(3): 282-288. doi: 10.3969/j.issn.1006-0111.2017.03.022
    [9] 聂力, 葛卫红.  白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析 . 药学实践与服务, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020
    [10] 刘留, 费素娟.  双歧杆菌三联活菌胶囊辅助根除幽门螺杆菌感染临床疗效的荟萃分析 . 药学实践与服务, 2016, 34(4): 380-384. doi: 10.3969/j.issn.1006-0111.2016.04.025
    [11] 万素馨, 黄道秋, 余蕾, 向毅, 方伟.  左氧氟沙星治疗耐多药肺结核疗效的系统评价/荟萃分析的质量评价 . 药学实践与服务, 2016, 34(6): 546-551. doi: 10.3969/j.issn.1006-0111.2016.06.016
    [12] 鲍思蔚, 张誉艺, 胡燕鸣, 翟晓波, 何志高.  氨曲南与头孢他啶治疗下呼吸道感染的荟萃分析 . 药学实践与服务, 2016, 34(1): 83-85,89. doi: 10.3969/j.issn.1006-0111.2016.01.022
    [13] 陶伊琳, 黄幼明, 林惠娥.  选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价 . 药学实践与服务, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
    [14] 田怀平, 高蕙敏, 张金莲, 唐跃年.  拉莫三嗪治疗儿童及青少年失神性癫痫的系统评价 . 药学实践与服务, 2015, 33(3): 263-268. doi: 10.3969/j.issn.1006-0111.2015.03.020
    [15] 林秀丽, 石鹤坤, 陈尚瑜, 陈锦珊.  复方甘草酸苷片治疗慢性湿疹的荟萃分析 . 药学实践与服务, 2015, 33(4): 380-382,384. doi: 10.3969/j.issn.1006-0111.2015.04.024
    [16] 樊蓉, 任天舒, 赵庆春, 史国兵.  西药常规治疗联用通心络胶囊治疗冠心病心绞痛疗效的荟萃分析 . 药学实践与服务, 2015, 33(1): 83-87. doi: 10.3969/j.issn.1006-0111.2015.01.024
    [17] 陈勇平, 刘云.  鲜竹沥雾化吸入治疗哮喘的临床观察 . 药学实践与服务, 2003, (1): 5-5.
    [18] 李翠静, 李惠芸.  盐酸氟桂利嗪胶囊致哮喘1例 . 药学实践与服务, 2000, (3): 184-184.
    [19] 郭胜才, 冯友根, 程荣珍, 蔡萍.  治疗哮喘的抗白三烯药物进展 . 药学实践与服务, 1999, (4): 205-207.
    [20] 孙福红, 王慧力, 高习文.  梵达浓缩银杏叶口服液治疗支气管哮喘的临床疗效观察 . 药学实践与服务, 1998, (3): 142-144.
  • 加载中
计量
  • 文章访问数:  2896
  • HTML全文浏览量:  403
  • PDF下载量:  326
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-10-10
  • 修回日期:  2018-12-29

糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析

doi: 10.3969/j.issn.1006-0111.2019.05.018

摘要: 目的 比较糠酸氟替卡松/维兰特罗复方剂(FF/VI)与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异。 方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库,纳入随机对照试验,采用Cochrane系统评价方法进行评价。 结果 共纳入10个研究,共9 811例患者。在疗效上,FF/VI组与对照组相比,提高患者的1秒用力呼气量谷值[WMD=0.09,95% CI(0.05,0.13),P=0.000]和哮喘控制测试评分[WMD=0.63,95% CI(0.24,1.03),P=0.002]。在耐受性方面,FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15,95% CI(0.98,1.36),P=0.000]。 结论 用FF/VI治疗哮喘在疗效方面具有优势,且具有良好的耐受性。其每日1次的用药频次可提高患者依从性,值得推荐使用。

English Abstract

林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
引用本文: 林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛. 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J]. 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
Citation: LIN Lili, YAO Nannan, WU Jue, LIU Zhihong, SONG Hongtao. Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
参考文献 (28)

目录

    /

    返回文章
    返回